Lixte Biotechnology Holdings, Inc. (LIXT) Dividend History

Company News

• LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

  LIXTE Biotechnology Holdings, Inc. has filed a request to withdraw its Registration Statement on Form S-1, as the company no longer intends to pursue a public offering at this time.

  GlobeNewswire Inc.
• LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

  Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system

  GlobeNewswire Inc.
• LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

  Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system

  GlobeNewswire Inc.
• Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

  LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing

  GlobeNewswire Inc.
• LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

  PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced the appointment of Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO).

  GlobeNewswire Inc.